DrugBiological
Vilobelimab clinical trials
Also written IFX-1 and CaCP29.
- studies test it
- 13
- open now
- 2
- in phase 3
- 2
- first study started
- 2011
Keep track of what changes. Save the vilobelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 11
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Glucocorticoid (1) · NI-0101 (1) · Bevacizumab (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses vilobelimab is read from its arms, and is right about nine times in ten.
Testing it · 13
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)RecruitingPhase 2PPD Development, LPNCT06703073Written as Cohort A: vilobelimab
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: VilobelimabRecruitingPhase 2PPD Development, LPNCT06701682Written as Cohort A: vilobelimab
- Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumTerminatedPhase 3InflaRx GmbHNCT05964413Written as vilobelimab
- Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.TerminatedPhase 2InflaRx GmbHNCT04812535Written as Vilobelimab
- Exploratory Study of IFX-1 in Patients With Pyoderma GangrenosumCompletedPhase 2InflaRx GmbHNCT03971643Written as vilobelimab
- Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 PneumoniaCompletedPhase 2/3InflaRx GmbHNCT04333420Written as IFX-1 + SOC
- Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.CompletedPhase 2InflaRx GmbHNCT03895801Written as IFX-1
- Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPATerminatedPhase 2InflaRx GmbHNCT03712345Written as IFX-1 low dose
- Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedPhase 2InflaRx GmbHNCT03487276Written as IFX-1
- Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2InflaRx GmbHNCT03001622Written as IFX-1
- Studying Complement Inhibition in Complex Cardiac SurgeryCompletedPhase 2InflaRx GmbHNCT02866825Written as IFX-1
- Studying Complement Inhibition in Early, Newly Developing Septic Organ DysfunctionCompletedPhase 2InflaRx GmbHNCT02246595Written as CaCP29
- Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29CompletedPhase 1InflaRx GmbHNCT01319903Written as CaCP29, a humanized monoclonal antibody
Codes
What other systems call vilobelimab · ClinicalTrials.gg INT001316
- MeSH (NLM) C000706656vilobelimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F5T0RF9ZJAVILOBELIMABConfirmed FDA, NLM
- NCI Thesaurus C172643VilobelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706656 | vilobelimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F5T0RF9ZJA | VILOBELIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C172643 | Vilobelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.